Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel

PURPOSE: For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednisone leads to superior survival and a higher response rate compared with mitoxantrone plus prednisone. We analyzed the efficacy of long-term treatment with ≥10 cycles of docetaxel, and validated...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kawahara, Takashi, Miyoshi, Yasuhide, Sekiguchi, Zenkichi, Sano, Futoshi, Hayashi, Narihiko, Teranishi, Jun-ichi, Misaki, Hiroshi, Noguchi, Kazumi, Kubota, Yoshinobu, Uemura, Hiroji
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2012
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3484044/
https://ncbi.nlm.nih.gov/pubmed/23118948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0048186
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki